SNX10 and inflammatory bowel disease: In addition, knocking out SNX10 using CRISPR/Cas9 or treating with the SnX10 inhibitor DC-SX029 blocks LPS release, caspase-5 activation, and downstream signaling, effectively alleviating intestinal barrier dysfunction induced by E. coli BL21 EVs.119 Although the E. coli BL21 used in this study is not a typical strain in the host gut, these findings are significant for research on IBD pathogenesis.